TEMPORAL RESPONSE PATTERNS OF ABROCITINIB AND DUPILUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POST HOC ANALYSIS OF THE JADE DARE TRIAL

被引：0
|
作者：
Trzeciak, Magdalena [1 ]
Chovatiya, Raj [2 ]
Geng, Bob [3 ]
Biswas, Pinaki [4 ]
Guler, Erman [5 ]
机构：
[1] Med Univ Gdansk, Dept Dermatol Venereol & Allergol, Gdansk, Poland
[2] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL USA
[3] Univ Calif San Diego, Dept Dermatol, Sch Med, San Diego, CA USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Istanbul, Turkiye
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4.6
引用
收藏
页码：30 / 31
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial
    Yao, Zhirong
    Xu, Aie
    He, Li
    Ding, Yangfeng
    Hu, Guohong
    Vyas, Shefali
    Wang, Bo
    Luo, Xin
    Li, Shiqi
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II23 - II24
  • [22] An evaluation of abrocitinib for moderate-to-severe atopic dermatitis
    Labib, Angelina
    Yosipovitch, Gil
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (11) : 1107 - 1118
  • [23] Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
    Shi, Vivian Y.
    Bhutani, Tina
    Fonacier, Luz
    Deleuran, Mette
    Shumack, Stephen
    Valdez, Hernan
    Zhang, Fan
    Chan, Gary L.
    Cameron, Michael C.
    Yin, Natalie C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 351 - 358
  • [24] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials
    Gooderham, Melinda J.
    Ardern-Jones, Michael R.
    Guttman-Yassky, Emma
    Ameen, Mahreen
    Simpson, Eric L.
    Chan, Gary
    Biswas, Pinaki
    Chiu, Wing S.
    Watkins, Melissa
    JEADV CLINICAL PRACTICE, 2023, 2 (04): : 753 - 763
  • [25] Patient-reported symptoms and quality of life in Australian patients with moderate-to-severe atopic dermatitis following treatment with abrocitinib: A post hoc analysis of JADE clinical trials
    Tan, Fiona
    Sinclair, Rodney
    Nas, Pablo Fernandez Pe
    Murrell, Dedee
    Foley, Peter
    Freeman, Michael
    Su, John
    Eisman, Samantha
    Rubel, Diana
    Spelman, Lynda
    Surian, Christine
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 28 - 28
  • [26] Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Gooderham, Melinda
    Chan, Gary
    Feeney, Claire
    Biswas, Pinaki
    Valdez, Hernan
    DiBonaventura, Marco
    Nduaka, Chudy
    Rojo, Ricardo
    JAMA DERMATOLOGY, 2020, 156 (08) : 863 - 873
  • [27] Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
    Reich, Kristian
    Lio, Peter A.
    Bissonnette, Robert
    Alexis, Andrew F.
    Lebwohl, Mark G.
    Pink, Andrew E.
    Kabashima, Kenji
    Boguniewicz, Mark
    Nowicki, Roman J.
    Valdez, Hernan
    Zhang, Fan
    DiBonaventura, Marco
    Cameron, Michael C.
    Clibborn, Claire
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (12): : 3228 - +
  • [28] Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis
    Nezamololama, Novin
    Crowley, Erika L.
    Gooderham, Melinda J.
    Papp, Kim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 911 - 917
  • [29] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
  • [30] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
12345